X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/03/25/2851702/0/en/Clinical-Data-on-the-Impact-of-Sotagliflozin-on-Stroke-and-Heart-Attack-Risk-Among-Four-Lexicon-Sponsored-Presentations-at-the-American-College-of-Cardiology-73rd-Annual-Scientific.html
https://www.fiercepharma.com/pharma/five-years-after-its-first-fda-rejection-lexicon-prepares-resubmit-its-type-1-diabetes
https://www.globenewswire.com//news-release/2023/11/12/2778645/0/en/INPEFA-sotagliflozin-Use-Associated-With-Early-Clinical-Benefit-in-Heart-Failure-and-Atherosclerotic-Events-in-Analysis-of-Clinical-Data.html
https://www.globenewswire.com//news-release/2023/11/02/2772389/0/en/Data-on-Early-Clinical-Benefit-for-INPEFA-Sotagliflozin-Will-Be-Among-Five-Lexicon-Sponsored-Presentations-at-the-American-Heart-Association-Scientific-Sessions-2023.html
https://www.globenewswire.com//news-release/2023/11/01/2771289/0/en/INPEFA-Sotagliflozin-Receives-Coverage-From-Express-Scripts-on-Its-Basic-and-High-Performance-Formularies-for-Commercially-Insured-Patients.html
https://www.globenewswire.com//news-release/2023/10/30/2769654/0/en/New-Data-Relating-to-Sotagliflozin-to-be-Presented-at-the-American-Society-of-Nephrology-ASN-Kidney-Week-2023-Annual-Meeting.html
https://www.globenewswire.com//news-release/2023/10/17/2761895/0/en/Data-From-Two-Studies-Demonstrating-Positive-Financial-Impact-of-INPEFA-Sotagliflozin-to-be-Presented-at-the-Academy-of-Managed-Care-Pharmacy-AMCP-Nexus-2023-National-Meeting.html
https://www.globenewswire.com//news-release/2023/10/11/2758417/0/en/Data-Demonstrating-Financial-Impact-of-INPEFA-Sotagliflozin-to-be-Presented-at-the-Academy-of-Managed-Care-Pharmacy-AMCP-Nexus-2023-National-Meeting.html
https://www.globenewswire.com//news-release/2023/10/09/2757020/0/en/INPEFA-Sotagliflozin-Receives-Preferred-Formulary-Status-With-Express-Scripts-For-Medicare-Patients.html
https://www.globenewswire.com//news-release/2023/09/28/2751264/0/en/Lexicon-to-Present-Post-Hoc-Analysis-of-Scored-Clinical-Trial-at-the-Heart-Failure-Society-of-America-HFSA-Annual-Scientific-Meeting-2023.html
https://www.globenewswire.com//news-release/2023/09/26/2749597/0/en/Lexicon-to-Present-Study-Results-Relating-to-Sotagliflozin-and-LX9211-at-the-59th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes-EASD.html
https://www.globenewswire.com//news-release/2023/08/21/2728703/0/en/Lexicon-to-Present-Analyses-of-INPEFA-sotagliflozin-Clinical-Study-Results-and-Changing-Patterns-of-Heart-Failure-Diagnoses-at-the-European-Society-of-Cardiology-ESC-Congress-2023.html
https://www.globenewswire.com/news-release/2023/08/08/2720716/0/en/Published-Analysis-of-Sotagliflozin-INPEFA-TM-Clinical-Data-Demonstrates-Significant-Reductions-in-the-Risk-of-Hospital-Readmissions-for-Heart-Failure.html
https://www.globenewswire.com/news-release/2023/06/20/2691015/0/en/Lexicon-to-Present-Study-Results-Relating-to-LX9211-and-INPEFA-Sotagliflozin-at-the-American-Diabetes-Association-s-83rd-Scientific-Sessions.html
https://www.prnewswire.com/news-releases/brand-institute-partners-with-lexicon-pharmaceuticals-on-the-brand-name-development-for-fda-approved-inpefa-sotagliflozin-301843320.html
https://pharmaphorum.com/news/sglt-latecomer-lexicon-gets-heart-failure-okay
https://health.economictimes.indiatimes.com/news/pharma/drug-approvals-launches/us-fda-approves-lexicon-pharmas-drug-for-heart-failure/100540367
https://endpts.com/fda-approves-lexicons-heart-failure-drug-after-defeat-in-diabetes/
https://www.globenewswire.com/news-release/2023/05/10/2666098/0/en/New-Analysis-Finds-Sotagliflozin-to-Be-a-Cost-Effective-Treatment-at-Commonly-Accepted-Willingness-to-Pay-Threshold-in-Patients-with-Worsening-Heart-Failure.html
https://www.globenewswire.com/news-release/2023/03/04/2620614/0/en/New-Analyses-of-Sotagliflozin-Showing-Time-to-Clinical-Benefit-Presented-at-The-American-College-of-Cardiology-s-72nd-Annual-Scientific-Session-Together-With-World-Heart-Federation.html
https://www.globenewswire.com/news-release/2023/02/20/2611315/0/en/New-Analyses-of-Sotagliflozin-to-Be-Presented-at-the-American-College-of-Cardiology-s-72nd-Annual-Scientific-Session-Together-With-World-Heart-Federation-s-World-Congress-of-Cardio.html
https://endpts.com/lexicon-slams-fda-over-hearing-denial-following-a-crl-for-its-sglt2-inhibitor-candidate/
https://www.fiercepharma.com/pharma/persistent-lexicon-still-working-get-audience-fda-type-1-diabetes-drug-sotagliflozin
https://www.globenewswire.com/news-release/2022/11/06/2549200/0/en/New-Analysis-of-SOLOIST-WHF-Results-Demonstrates-Sotagliflozin-s-Significant-Effect-in-Reducing-the-Risk-of-Hospital-Readmissions-for-Heart-Failure.html
https://www.globenewswire.com/news-release/2022/10/31/2544632/0/en/New-Analyses-of-Sotagliflozin-From-the-SOLOIST-WHF-and-SCORED-Trials-in-High-Cardiovascular-Risk-Patients-to-be-Presented-at-the-American-Heart-Association-Scientific-Sessions-2022.html
https://www.globenewswire.com/news-release/2022/10/02/2526424/0/en/New-Analysis-of-SOLOIST-WHF-Trial-Underscores-Sotagliflozin-s-Effect-on-Reducing-Recurrent-Heart-Failure-Events.html
https://www.globenewswire.com/news-release/2022/08/22/2502512/0/en/Lexicon-Pharmaceuticals-Highlights-Publications-Relating-to-Sotagliflozin-s-Differentiated-Dual-SGLT1-and-SGLT2-Mechanism-of-Action-and-Potential-Implications-for-Cardiovascular-Di.html
https://www.globenewswire.com/news-release/2022/07/27/2486783/0/en/Lexicon-Announces-FDA-Acceptance-of-New-Drug-Application-for-Sotagliflozin-to-Treat-Heart-Failure.html
https://endpts.com/fda-again-spells-out-safety-concerns-with-oral-while-denying-lexicons-attempt-to-overturn-a-crl/
https://seekingalpha.com/news/3843937-lexicon-refiles-for-fda-approval-of-sotagliflozin-to-treat-heart-failure
https://www.globenewswire.com/news-release/2022/04/02/2415169/0/en/Sotagliflozin-Improved-Outcomes-in-Patients-With-and-Without-Prior-Cardiovascular-Disease-in-New-Analysis-Presented-at-the-American-College-of-Cardiology-s-71st-Annual-Scientific-S.html
https://www.benzinga.com/general/biotech/22/02/25868602/lexicon-pharma-pulls-sotagliflozin-us-application-due-to-technical-issue-shares-fall
https://trialsitenews.com/lexicon-files-nda-with-fda-seeking-approval-of-sotagliflozin-for-the-treatment-of-heart-failure-in-adults-with-type-2-diabetes/
https://www.globenewswire.com/news-release/2021/12/30/2359411/0/en/Lexicon-Submits-New-Drug-Application-for-Sotagliflozin-for-the-Treatment-of-Heart-Failure-in-Adults-With-Type-2-Diabetes.html
https://www.globenewswire.com/news-release/2021/11/14/2333731/0/en/Lexicon-s-Sotagliflozin-Demonstrates-Benefits-in-Heart-Failure-and-Blood-Glucose-Control-Across-the-Full-Range-of-Kidney-Function-in-New-Analysis-of-Clinical-Data.html
https://www.globenewswire.com/news-release/2021/08/23/2284663/0/en/Lexicon-s-Sotagliflozin-Demonstrates-Additional-Compelling-Benefits-in-Reducing-Cardiovascular-Endpoints-Results-from-Soloist-and-Scored-Trials.html
https://www.prnewswire.com/news-releases/early-use-of-sotagliflozin-provides-benefits-for-people-with-type-2-diabetes-with-chronic-kidney-disease-or-heart-failure-301322211.html
http://www.lexpharma.com/media-center/news/773-lexicon-pharmaceuticals-provides-regulatory-update-on-sotagliflozin-in-heart-failure#:~:text=Lexicon%20Pharmaceuticals%20Provides%20Regulatory%20Update,2021%20%E2%80%93%20Lexicon%20Pharmaceuticals%2C%20Inc.&text=This%20regulatory%20feedback%20clears%20a,potential%20NDA%20filing%20in%202021.
https://www.globenewswire.com/news-release/2020/11/17/2127892/0/en/Results-From-SOLOIST-and-SCORED-Outcomes-Studies-Presented-at-Late-Breaking-Science-Session-of-American-Heart-Association-Scientific-Sessions-and-Published-in-The-New-England-Journ.html
http://www.lexpharma.com/media-center/news/748-lexicon-pharmaceuticals-announces-topline-phase-3-data-from-four-phase-3-sotagliflozin-studies-in-type-2-diabetes
https://www.globenewswire.com/news-release/2020/01/09/1968558/0/en/Retrotope-Expands-its-Drug-Pipeline-with-the-First-Dosing-of-RT001-in-patients-with-Friedreich-s-ataxia-FA.html
https://www.reuters.com/article/us-lexicon-pharm-stocks/lexicon-pharma-shares-plummet-after-fda-denies-appeal-against-drug-rejection-idUSKBN1Y61H5?feedType=RSS&feedName=healthNews
https://www.fiercebiotech.com/biotech/fda-nixes-lexicon-s-diabetes-hopeful-zynquista-again
https://www.fiercebiotech.com/biotech/sanofi-to-pay-260m-to-exit-lexicon-diabetes-pact
https://endpts.com/sanofi-takes-a-260m-hit-to-extricate-itself-from-a-disastrous-alliance-with-lexicon/
http://www.pharmafile.com/news/525302/sanofi-ends-partnership-lexicon-after-release-phase-3-data
https://www.fiercepharma.com/pharma/sanofi-exits-zynquista-collab-following-phase-3-tests-but-lexicon-considers-notice-to-be
https://www.fiercepharma.com/pharma/astrazeneca-s-farxiga-follows-rival-zynquista-to-fda-rejection-type-1-diabetes?utm_source=internal&utm_medium=rss
Market Place
Share 
